Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) and BioNxt Solutions (OTCMKTS:BNXTF – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.
Insider & Institutional Ownership
79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Catalyst Pharmaceuticals and BioNxt Solutions’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Catalyst Pharmaceuticals | 37.08% | 35.76% | 31.31% |
| BioNxt Solutions | N/A | N/A | -1,173.20% |
Volatility and Risk
Valuation and Earnings
This table compares Catalyst Pharmaceuticals and BioNxt Solutions”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Catalyst Pharmaceuticals | $596.96 million | 6.46 | $214.33 million | $1.74 | 18.10 |
| BioNxt Solutions | $20,000.00 | 1,590.21 | -$5.03 million | ($0.05) | -4.67 |
Catalyst Pharmaceuticals has higher revenue and earnings than BioNxt Solutions. BioNxt Solutions is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Catalyst Pharmaceuticals and BioNxt Solutions, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Catalyst Pharmaceuticals | 0 | 6 | 1 | 2 | 2.56 |
| BioNxt Solutions | 0 | 0 | 0 | 0 | 0.00 |
Catalyst Pharmaceuticals presently has a consensus target price of $32.00, suggesting a potential upside of 1.62%. Given Catalyst Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Catalyst Pharmaceuticals is more favorable than BioNxt Solutions.
Summary
Catalyst Pharmaceuticals beats BioNxt Solutions on 14 of the 15 factors compared between the two stocks.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
About BioNxt Solutions
BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
